Market Cap 219.45B
Revenue (ttm) 54.07B
Net Income (ttm) 7.04B
EPS (ttm) N/A
PE Ratio 16.43
Forward PE 15.74
Profit Margin 13.01%
Debt to Equity Ratio 0.73
Volume 6,297,100
Avg Vol 5,034,198
Day's Range N/A - N/A
Shares Out 3.10B
Stochastic %K 5%
Beta 0.38
Analysts Strong Sell
Price Target $85.52

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modi...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 44 20 3749 5000
Fax: 44 1223 352 858
Address:
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom
Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 9:48 PM
$AZN's ENHERTU continues to dominate the HER2-low cancer market with projected 9.4% CAGR through 2034. DATROWAY (Dato-DXd) Phase III progress and strong uptake in breast/gastric cancers reinforce AstraZeneca's leadership. With 63% of breast cancers classified HER2-low, pipeline depth positions AZN for sustained oncology growth. https://www.prnewswire.com/news-releases/her2-low-cancers-market-set-to-register-immense-growth-at-a-cagr-of-9-4-during-the-study-period-20202034--delveinsight-302486020.html
0 · Reply
Xtrnr
Xtrnr Jun. 18 at 12:39 PM
$AZN $BDRX https://www.gurufocus.com/news/2933277/biodexa-hits-key-milestone-for-its-type-1-diabetes-candidate-tolimidone-enrolls-first-patient-in-phase-2a-study-bdrx-stock-news
0 · Reply
G101SPM
G101SPM Jun. 17 at 7:12 PM
#SHOWTIME ^ J.P. Morgan European Healthcare Forum (June 18) Scheduled to appear: $AZN, $BAYN, $FME, $NOVN, $RO, $SDZ ^ European Society for Medical Oncology Gynaecological Cancers Congress (June 18) Scheduled to appear: $ANIX, $IMNN
0 · Reply
Dumb_money_big_gains
Dumb_money_big_gains Jun. 17 at 5:21 PM
$ARTV lots of biotech acquisitions happening lately… $AZN $LLY $NVS
0 · Reply
RitaTodd
RitaTodd Jun. 17 at 3:35 PM
0 · Reply
OptionRunners
OptionRunners Jun. 17 at 3:29 PM
Cut losses on $AZN calls at $0.36. Moving back towards lows again. Will see if this weekly uptrend holds in the next 1-2 weeks for a potential re-entry.
1 · Reply
OptionRunners
OptionRunners Jun. 17 at 1:32 PM
$AZN down with other pharmas on Trump's tariff comments 😒 https://x.com/DeItaone/status/1934898127372509250
0 · Reply
RAAAAAM
RAAAAAM Jun. 17 at 12:34 PM
$PRPH PT 0.78 but we cross 0.84 then off to 0.93 then $1+ $AZN
0 · Reply
peanutscream
peanutscream Jun. 17 at 10:56 AM
$FGEN they could communicate the completion of the sale of the chinese division to $AZN any day now!
0 · Reply
OptionRunners
OptionRunners Jun. 16 at 4:00 PM
Added a little more (small add) $AZN calls at $0.64. Averaged at $0.85 now. May add more later depending on how the week finishes. Coming back up on support and at a retest of the weekly breakout which is at $73.25-$73.50
0 · Reply
Latest News on AZN
AstraZeneca CEO Pascal Soriot on breast cancer drug trial

Jun 2, 2025, 11:06 AM EDT - 19 days ago

AstraZeneca CEO Pascal Soriot on breast cancer drug trial


Why AstraZeneca May Be 2025's Most Underrated Pharma Stock

May 25, 2025, 4:50 AM EDT - 27 days ago

Why AstraZeneca May Be 2025's Most Underrated Pharma Stock


35 Barron's Pro-Picks: One Ideal May DiviDog

May 18, 2025, 4:51 AM EDT - 4 weeks ago

35 Barron's Pro-Picks: One Ideal May DiviDog

AGNC ASIX BDX CRM EPD FLMI FOX


Pharma firms maastraz

Apr 29, 2025, 12:06 PM EDT - 7 weeks ago

Pharma firms maastraz

GSK NVO NVS


AstraZeneca CEO talks tariffs, first quarter earnings

Apr 29, 2025, 11:35 AM EDT - 7 weeks ago

AstraZeneca CEO talks tariffs, first quarter earnings


AstraZeneca says may face further import tax fine from China

Apr 29, 2025, 2:10 AM EDT - 7 weeks ago

AstraZeneca says may face further import tax fine from China


AstraZeneca's Q1 2025 Financial Results

Apr 29, 2025, 2:00 AM EDT - 7 weeks ago

AstraZeneca's Q1 2025 Financial Results


Selling America, Buying Europe - My Picks

Apr 20, 2025, 9:15 AM EDT - 2 months ago

Selling America, Buying Europe - My Picks

ASML NVO


Rage_Against_The_Machine
Rage_Against_The_Machine Jun. 19 at 9:48 PM
$AZN's ENHERTU continues to dominate the HER2-low cancer market with projected 9.4% CAGR through 2034. DATROWAY (Dato-DXd) Phase III progress and strong uptake in breast/gastric cancers reinforce AstraZeneca's leadership. With 63% of breast cancers classified HER2-low, pipeline depth positions AZN for sustained oncology growth. https://www.prnewswire.com/news-releases/her2-low-cancers-market-set-to-register-immense-growth-at-a-cagr-of-9-4-during-the-study-period-20202034--delveinsight-302486020.html
0 · Reply
Xtrnr
Xtrnr Jun. 18 at 12:39 PM
$AZN $BDRX https://www.gurufocus.com/news/2933277/biodexa-hits-key-milestone-for-its-type-1-diabetes-candidate-tolimidone-enrolls-first-patient-in-phase-2a-study-bdrx-stock-news
0 · Reply
G101SPM
G101SPM Jun. 17 at 7:12 PM
#SHOWTIME ^ J.P. Morgan European Healthcare Forum (June 18) Scheduled to appear: $AZN, $BAYN, $FME, $NOVN, $RO, $SDZ ^ European Society for Medical Oncology Gynaecological Cancers Congress (June 18) Scheduled to appear: $ANIX, $IMNN
0 · Reply
Dumb_money_big_gains
Dumb_money_big_gains Jun. 17 at 5:21 PM
$ARTV lots of biotech acquisitions happening lately… $AZN $LLY $NVS
0 · Reply
RitaTodd
RitaTodd Jun. 17 at 3:35 PM
0 · Reply
OptionRunners
OptionRunners Jun. 17 at 3:29 PM
Cut losses on $AZN calls at $0.36. Moving back towards lows again. Will see if this weekly uptrend holds in the next 1-2 weeks for a potential re-entry.
1 · Reply
OptionRunners
OptionRunners Jun. 17 at 1:32 PM
$AZN down with other pharmas on Trump's tariff comments 😒 https://x.com/DeItaone/status/1934898127372509250
0 · Reply
RAAAAAM
RAAAAAM Jun. 17 at 12:34 PM
$PRPH PT 0.78 but we cross 0.84 then off to 0.93 then $1+ $AZN
0 · Reply
peanutscream
peanutscream Jun. 17 at 10:56 AM
$FGEN they could communicate the completion of the sale of the chinese division to $AZN any day now!
0 · Reply
OptionRunners
OptionRunners Jun. 16 at 4:00 PM
Added a little more (small add) $AZN calls at $0.64. Averaged at $0.85 now. May add more later depending on how the week finishes. Coming back up on support and at a retest of the weekly breakout which is at $73.25-$73.50
0 · Reply
OptionRunners
OptionRunners Jun. 16 at 1:34 PM
Bought $AZN July 18th $77.50 calls at $0.92
0 · Reply
malaga222
malaga222 Jun. 15 at 8:14 PM
$AZN wouldn't touch this with a barge pole
0 · Reply
Ned_Nosurname
Ned_Nosurname Jun. 15 at 12:17 AM
$AZN https://x.com/anthonystaj/status/1933887218092741020
0 · Reply
ZacksResearch
ZacksResearch Jun. 13 at 5:45 PM
$TEM's strategic moves are paying off — but is the valuation too rich? 🤔 🚀 Shares surged 77% over the past year, outpacing the industry's 39.7% growth. 💡 Recent partnerships with $AZN and $ILMN focus on expanding relationships and enhancing AI-driven precision medicine technologies. 📉 Yet, it's trading at a forward P/S of 8.85x vs. the industry's 6.34x and holds a Value Score of F. Dive into the full analysis here 👉 https://www.zacks.com/commentary/2498512/tempus-ais-expanding-ties-boost-novel-rd-efforts-and-market-reach?cid=sm-stocktwits-2-2498512-body&ADID=SYND_STOCKTWITS_TWEET_2_2498512_BODY
0 · Reply
mikesterz7
mikesterz7 Jun. 13 at 1:41 PM
$AZN 🚨 AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate
0 · Reply
StocktwitsNews
StocktwitsNews Jun. 13 at 12:33 PM
AstraZeneca Inks $5.3B Deal With CSPC Pharma For Developing New Oral Drug Candidate, But Retail’s In No Mood To Cheer $AZN $QQQ $QQQM https://stocktwits.com/news/equity/markets/astrazeneca-inks-5.3-billion-deal-with-cspc-pharma-for-new-drug-candidates/chli5sARRbG
0 · Reply
LiveSquawk
LiveSquawk Jun. 13 at 11:45 AM
$AZN | AstraZeneca Signs $5.2B Deal To Develop Drugs For Chronic Disease With Chinese Biotech - FT https://www.ft.com/content/fd23a402-5be9-447c-b511-8179a41f280d
0 · Reply
DonCorleone77
DonCorleone77 Jun. 13 at 10:28 AM
$AZN AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working together on high priority targets, the collaboration aims to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications. Under the terms of the agreement, AstraZeneca and CSPC agree to discover and develop pre-clinical candidates for multiple targets with the potential to treat diseases across chronic indications, including a pre-clinical small molecule oral therapy for immunological diseases.
0 · Reply
miggy99
miggy99 Jun. 12 at 5:28 PM
$AZN Is the next Alexion Pharma stock price $182.50 🚀🚀🥳🥳
0 · Reply
DonCorleone77
DonCorleone77 Jun. 12 at 10:22 AM
$MRNA $NVAX $BNTX $AZN $BMY RFK Jr. names eight members to vaccine panel, WSJ reports Health Secretary Robert F. Kennedy Jr. has appointed eight new members to the advisory immunization committee, including vaccine opponents, The Wall Street Journal's Liz Essley Whyte and Dominique Mosbergen report. The new panel will review both new and existing vaccine recommendations. Kennedy's move came two days after abruptly removing all 17 of the prior members of the Advisory Committee on Immunization Practices. "All of these individuals are committed to evidence-based medicine, gold-standard science, and common sense," RFK Jr. said. Publicly traded companies in the pharmaceutical and vaccine space include Moderna (MRNA), Novavax (NVAX), BioNTech (BNTX), AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
1 · Reply
DonCorleone77
DonCorleone77 Jun. 11 at 10:02 PM
$AZN $GSK $NVS $RHHBY $BMY RFK Jr. names new CDC vaccine advisory panel picks, STAT reports HHS Secretary Robert F. Kennedy Jr. announced eight new members that will sit on the expert panel that advises the Centers for Disease Control and Prevention, or CDC, on vaccine policy, and "said they would review the current vaccine schedule, as well as evaluate new shots." These appointments follow Kennedy dismissing every member of the committee just days ago. Publicly traded companies in the space include the following: AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
0 · Reply
surfmav
surfmav Jun. 11 at 3:35 PM
$SMCI, $AZN, $NVDA, $SFTBY, $ERIC: https://www.supermicro.com/en/pressreleases/supermicro-unveils-industrys-broadest-enterprise-ai-solution-portfolio-nvidia https://www.ericsson.com/en/news/2025/6/ericsson-and-supermicro-advance-enterprise-connectivity-for-edge-ai-systems Hope this helps, or at least entertains, someone today. As always, GLTA. Background links: https://www.supermicro.com/en/solutions/ericsson https://www.rcrwireless.com/20250528/ai-ml/ericsson-ai-factory https://finance.yahoo.com/news/nvidia-nvda-help-build-sweden-181627462.html https://www.mobileworldlive.com/europe/ericsson-among-industry-giants-backing-swedish-ai-drive/ https://www.ericsson.com/en/news/2025/5/ericsson-in-consortium-to-develop-swedish-ai-factory https://www.lightreading.com/6g/nvidia-sees-huawei-not-intel-as-the-big-ai-ran-6g-rival https://www.ericsson.com/en/press-releases/2/2025/3/ericsson-softbank-corp--achieve-milestones-in-ai-ran-integration-joint-research-and-development https://www.capacitymedia.com/article/2ehtn03vb1sioffl3xo8w/news/article-ericsson-softbank
0 · Reply